0
Biofrontera AG Banner Image

Biofrontera AG has reached its limit for free report views

Work for Biofrontera AG? Upgrade Your Profile and unlock all your annual reports.

Biofrontera AG

  • Ticker BFRA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Biofrontera AG Logo Image
  • 51-200 Employees
  • Based in Leverkusen, Germany
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz®, a topical prescription drug, and medicalMore device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication XepiTM for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
Biofrontera AG

Most Recent Annual Report

Biofrontera AG MOST RECENT 2020 Annual Report

Report Locked. Biofrontera AG has reached its limit for free report views.

Older/Archived Annual Reports